Dexcom (DXCM) Research & Development (2010 - 2026)

Dexcom (DXCM) has 17 years of Research & Development data on file, last reported at $145.3 million in Q1 2026.

• On a quarterly basis, Research & Development changed 0.07% year-over-year to $145.3 million in Q1 2026; TTM through Mar 2026 was $599.2 million, a 7.75% increase from a year earlier, with the FY2025 full-year figure at $599.1 million, up 8.45% from the prior year.
• Research & Development for Q1 2026 stood at $145.3 million, down from $148.2 million in the prior quarter.
• Over the last five years, Research & Development for DXCM reached as high as $157.5 million in Q3 2025 and fell as low as $110.3 million in Q3 2022.
• Historically, Research & Development has averaged $134.5 million across 5 years, with a median of $136.0 million in 2024.
• On a YoY basis, Research & Development climbed as much as 24.22% in 2022 and fell as far as 22.36% in 2022.
• Year by year, Research & Development stood at $116.3 million in 2022, then rose by 17.02% to $136.1 million in 2023, then advanced by 2.5% to $139.5 million in 2024, then increased by 6.24% to $148.2 million in 2025, then dropped by 1.96% to $145.3 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $145.3 million in Q1 2026, $148.2 million in Q4 2025, and $157.5 million in Q3 2025.